Nelfinavir - major trial results at retroviruses conference. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Nelfinavir - major trial results at retroviruses conference. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

AIDS Treat News. 1997 Feb 21;(No 265):3-4. Unique Identifier : AIDSLINE AIDS/97702528

Abstract: Nelfinavir (Viracept) is expected to be approved soon by the Food and Drug Administration (FDA). This fourth protease inhibitor appears to have fewer side effects, a different resistance profile, and offers new options for combination therapy. Results from all trials by the manufacturer, Agouron, showed statistically significant improvements in CD4 counts and viral load, with the best results associated with combination therapy. No clinical endpoint results are available yet.

Keywords: Anti-HIV Agents/THERAPEUTIC USE CD4 Lymphocyte Count Clinical Trials Drug Therapy, Combination HIV Infections/*DRUG THERAPY HIV Protease Inhibitors/*ADMINISTRATION & DOSAGE/THERAPEUTIC USE Human Isoquinolines/*ADMINISTRATION & DOSAGE/THERAPEUTIC USE Lamivudine/THERAPEUTIC USE Stavudine/THERAPEUTIC USE Sulfonic Acids/*ADMINISTRATION & DOSAGE/THERAPEUTIC USE Viral Load Zidovudine/THERAPEUTIC USE NEWSLETTER ARTICLE
970830
M9781223

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .